Dermatology

Nemolizumab exclusively targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.

The indication is for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation.

The approval builds on previous indications for tapinarof, an aryl hydrocarbon receptor agonist, for the topical treatment of atopic dermatitis.

Currently, the treatment is undergoing evaluation in a phase 2a trial.

If approved, the new indications include children 6 years and older with moderate to severe plaque psoriasis and children 5 years and older with active juvenile psoriatic arthritis.

Treatment often involves a combination of preventive measures, topical therapies, and systemic treatments.

Bimekizumab-bkzx is the first and only approved medication that targets both interleukin (IL) 17F and IL-17A.

The indication is for patients 12 and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.

About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.

The approval comes after the phase 3 clinical trials MVOR-1 (NCT05296629) and MVOR-2 (NCT05343455).

At weeks 16 and 24, approximately 57% and 60% of patients with moderate to severe atopic dermatitis, respectively, achieved at least 75% improvement in Eczema Area and Severity Index score.

The FDA assigned a Prescription Drug User Fee Act action date of May 22, 2025.

If approved, delgocitinib cream would be the first US treatment indicated for moderate to severe chronic hand eczema.

There is a need for continued research and awareness in the diagnosis and management of alopecia in diverse populations.

Lebrikizumab (Ebglyss; Eli and Lilly Company) is a monthly maintenance injection with proven efficacy in adults and children aged 12 to 18 years.

Not only do diverse clinical cohorts improve the strength of the data, but it improves public trust in clinicians and the medical system as a whole.

The company also submitted data from the ongoing phase 2 study, demonstrating the improvements of the investigational drug for symptoms of overall disease severity.

In July 2024, the FDA approved the supplemental new drug application for roflumilast cream 0.15% for patients 6 years and older.

Pediatric patients weighing 20 kg to <50 kg should take 20 mg of apremilast twice daily and children weighing at least 50 kg should take 30 mg twice daily.

The study authors recommend that health care professionals are aware of the connections, notably in adolescent patients and those with moderate to severe psoriasis.

Nemolizumab is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, which drives disease mechanisms in prurigo nodularis.

The systematic review summarized all available evidence on the subject, finding that intravenous immunoglobulin could have a role in treatment.

Intravenous Immunoglobulin as a therapy for patients with pyoderma gangrenosum could open new treatment avenues for the rare and challenging condition.

The Lancet published data from DELTA 1 and DELTA 2 trials that displayed treatment success among individuals treated with delgocitinib cream.

The decision expands the use of incobotulinumtoxinA beyond treatment of frown lines.

Individuals that followed the Mediterranean diet with EPA-DHA supplements displayed an increase in omega-3 levels which improved clinical appearance.

The importance of protecting the skin is often underestimated by patients

Roflumilast is approved as a once daily and steroid-free cream for rapid disease clearance and significant reduction in itch and for long-term disease control.